IL17A and myeloid sarcoma: Significantly, in both MBP and anti-CD3 stimulated MS-derived cells, PP14·Fcγ1 significantly inhibited both IFN-γ and IL-17 secretion (Fig. S1, C and D, respectively), suggesting it's capability to inhibit these cytokines in both normal and MS pathological conditions despite the predominant Th17 response in the latter.